WallStreetZenWallStreetZen

NASDAQ: HROW
Harrow Inc Stock

$16.79+0.03 (+0.18%)
Updated May 20, 2024
HROW Price
$16.79
Fair Value Price
N/A
Market Cap
$594.06M
52 Week Low
$7.60
52 Week High
$24.19
P/E
-18.25x
P/B
9.81x
P/S
3.38x
PEG
N/A
Dividend Yield
N/A
Revenue
$138.68M
Earnings
-$31.33M
Gross Margin
69.8%
Operating Margin
-6.02%
Profit Margin
-22.6%
Debt to Equity
3.89
Operating Cash Flow
$7M
Beta
0.91
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

HROW Overview

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Zen Score

Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how HROW scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

HROW is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
HROW is poor value based on its book value relative to its share price (9.81x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.21x)
P/B vs Industry Valuation
HROW is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more HROW due diligence checks available for Premium users.

Be the first to know about important HROW news, forecast changes, insider trades & much more!

HROW News

Valuation

HROW price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-18.25x
Industry
-1.08x
Market
31.12x

HROW price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
9.81x
Industry
2.21x
HROW is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

HROW's financial health

Profit margin

Revenue
$34.6M
Net Income
-$13.6M
Profit Margin
-39.2%
HROW's Earnings (EBIT) of -$8.35M... subscribe to Premium to read more.
Interest Coverage Financials
HROW's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$295.5M
Liabilities
$235.3M
Debt to equity
3.89
HROW's short-term assets ($125.46M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HROW's long-term liabilities ($193.58M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HROW's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
HROW's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$4.6M
Investing
-$110.0k
Financing
-$809.0k
HROW's operating cash flow ($7.43M)... subscribe to Premium to read more.
Debt Coverage Financials

HROW vs Pharmaceutical Stocks

TickerMarket Cap1d %P/EP/B
HROW$594.06M+0.18%-18.25x9.81x
PETQ$599.50M+0.90%80.60x2.54x
SIGA$536.97M-0.79%6.86x3.25x
ESPR$469.86M+5.08%-2.56x-1.60x
PAHC$738.38M-0.92%55.24x2.73x

Harrow Stock FAQ

What is Harrow's quote symbol?

(NASDAQ: HROW) Harrow trades on the NASDAQ under the ticker symbol HROW. Harrow stock quotes can also be displayed as NASDAQ: HROW.

If you're new to stock investing, here's how to buy Harrow stock.

What is the 52 week high and low for Harrow (NASDAQ: HROW)?

(NASDAQ: HROW) Harrow's 52-week high was $24.19, and its 52-week low was $7.60. It is currently -30.59% from its 52-week high and 120.92% from its 52-week low.

How much is Harrow stock worth today?

(NASDAQ: HROW) Harrow currently has 35,381,935 outstanding shares. With Harrow stock trading at $16.79 per share, the total value of Harrow stock (market capitalization) is $594.06M.

Harrow stock was originally listed at a price of $120.00 in Sep 28, 2007. If you had invested in Harrow stock at $120.00, your return over the last 16 years would have been -86.01%, for an annualized return of -11.57% (not including any dividends or dividend reinvestments).

How much is Harrow's stock price per share?

(NASDAQ: HROW) Harrow stock price per share is $16.79 today (as of May 20, 2024).

What is Harrow's Market Cap?

(NASDAQ: HROW) Harrow's market cap is $594.06M, as of May 22, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Harrow's market cap is calculated by multiplying HROW's current stock price of $16.79 by HROW's total outstanding shares of 35,381,935.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.